Background: Ursodeoxycholic acid (UDCA) reduces symptomatic gallstone disease after Roux-en-Y gastric bypass (RYGB). The beneficial effect of UDCA is reduced by poor adherence.
Objectives: We aimed to identify factors associated with poor adherence to UDCA or placebo after bariatric surgery.